<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727724</url>
  </required_header>
  <id_info>
    <org_study_id>M18ACX</org_study_id>
    <nct_id>NCT03727724</nct_id>
  </id_info>
  <brief_title>Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer</brief_title>
  <acronym>AFACET</acronym>
  <official_title>Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm open-label multi-center phase II study, investigating disease control&#xD;
      rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with&#xD;
      advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate after 18 weeks</measure>
    <time_frame>18 weeks</time_frame>
    <description>To determine the disease control rate at 18 weeks of afatinib and cetuximab treatment in patients with NSCLC harboring an EGFR exon 20 insertion mutation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Scans every 6 weeks until tumor progression, start of another treatment or death.</time_frame>
    <description>Objective tumor response (complete response and partial response)determined by RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (intensity and incidence of adverse events)</measure>
    <time_frame>Up to 30 days after last study drug intake.</time_frame>
    <description>Safety as indicated by intensity and incidence of adverse events, graded according to NCI CTCAE Version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Scans every 6 weeks until tumor progression</time_frame>
    <description>Time from documentation of tumor response to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Until progression, every 6 weeks up to progression</time_frame>
    <description>Time from the date of start treatment to the date of the first documented tumor progression as determined by RECIST1.1, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 6 weeks up to death</time_frame>
    <description>Time form date of start treatment to the date of death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Genetic profiling to assess predictors of response and resistance - circulating free (cf)DNA</measure>
    <time_frame>At baseline, cycle 1 day 15 and at treatment discontinuation (expected 6 months after start)</time_frame>
    <description>cfDNA samples will be collected to assess predictors of response and resistance.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Afatinib plus cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Afatinib, 40 mg once daily, orally.&#xD;
Cetuximab, 500 mg/m² intravenously, every 2 weeks.&#xD;
Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Afatinib plus cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Injection</description>
    <arm_group_label>Afatinib plus cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically or cytologically confirmed stage IV non-small cell lung cancer,&#xD;
             harboring an EGFR exon 20 insertion mutation.&#xD;
&#xD;
          -  18 years or older at time of study entry.&#xD;
&#xD;
          -  Life expectancy of at least three months.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 1).&#xD;
&#xD;
          -  Measurable disease, according to RECIST 1.1.&#xD;
&#xD;
          -  At baseline adequate fresh or archived tissue from a histological biopsy or a&#xD;
             cellblock obtained by fine needle aspiration of a tumor lesion that is not radiated&#xD;
             prior to biopsy, must be available. Baseline tissue samples must have been obtained&#xD;
             after the last line of systemic therapy prior to study entry.&#xD;
&#xD;
          -  Adequate normal organ and marrow function as defined below:&#xD;
&#xD;
          -  Absolute leukocyte count ≥ 3 x 109/L (&gt; 3000 per mm3)&#xD;
&#xD;
          -  Platelet count ≥ 75 x 109/L (&gt;75,000 per mm3)&#xD;
&#xD;
          -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 x&#xD;
             institutional upper limit of normal unless liver metastases are present, in which case&#xD;
             it must be ≤ 5x upper limit of normal (ULN).&#xD;
&#xD;
          -  Serum creatinine clearance &gt;30 mL/min by the Cockcroft-Gault formula or by 24-hour&#xD;
             urine collection for determination of creatinine clearance.&#xD;
&#xD;
          -  Women of child-bearing potential: these subjects must have a negative serum pregnancy&#xD;
             test within 7 days prior to the first dose of study treatment and agree to use highly&#xD;
             effective contraception, as defined in section 5.2.2, from 7 days prior to enrollment,&#xD;
             throughout the treatment period and for seven months after completion of the treatment&#xD;
             with cetuximab.&#xD;
&#xD;
          -  Males must agree to take appropriate precautions to avoid fathering a child from the&#xD;
             first dose of study treatment through 3 months after the final administration of&#xD;
             investigational drugs.&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
          -  Ability to give written informed consent before patient registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 2 weeks.&#xD;
&#xD;
          -  Prior treatment with EGFR targeting antibodies (prior treatment with EGFR TKI's is&#xD;
             allowed).&#xD;
&#xD;
          -  Other active malignancy.&#xD;
&#xD;
          -  History of hypersensitivity to afatinib or cetuximab.&#xD;
&#xD;
          -  Major surgery (excluding diagnostic procedures e.g. mediastinoscopy or video assisted&#xD;
             thoracic surgery (VATS) biopsy) within 28 days of the start of study treatment.&#xD;
&#xD;
          -  Radiotherapy less than two weeks prior to the start of study treatment.&#xD;
&#xD;
          -  Symptomatic brain metastases.&#xD;
&#xD;
          -  Breast feeding is not allowed during study treatment.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including ongoing or active infection, symptomatic&#xD;
             congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac&#xD;
             arrhythmia, active peptic ulcer disease or gastritis, myocardial infarction within 12&#xD;
             months prior to the study entry, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements or compromise the ability of the subject to&#xD;
             give written informed consent. Any other concomitant serious illness or organ system&#xD;
             dysfunction which in the opinion of the investigator would either compromise patient&#xD;
             safety or interfere with the evaluation of the safety and anti-tumor activity of the&#xD;
             test drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J de Langen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J de Langen, MD, PhD</last_name>
    <phone>0031205129111</phone>
    <email>j.d.langen@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>B van Veggel, MD</last_name>
    <phone>0031205129111</phone>
    <email>b.v.veggel@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>North-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joop de Langen, MD, PhD</last_name>
      <phone>+3120512</phone>
      <phone_ext>2958</phone_ext>
      <email>j.d.langen@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bianca van Veggel, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>2958</phone_ext>
      <email>b.v.veggel@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Hashemi, MD</last_name>
      <phone>+31-20-4443999</phone>
      <email>S.Hashemi@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.J. van der Wekken, MD, PhD</last_name>
      <phone>+31-50-3616161</phone>
      <email>a.j.van.der.wekken@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Dingemans, MD, PhD</last_name>
      <phone>+31-43-3876543</phone>
      <email>a.dingemans@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

